CYT 6091

Drug Profile

CYT 6091

Alternative Names: AURIMUNE; Aurimune-T; CYT-6091

Latest Information Update: 07 Apr 2016

Price : $50

At a glance

  • Originator CytImmune Sciences
  • Class Antineoplastics; Tumour necrosis factors
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 07 Apr 2016 This programme is in active development
  • 16 Sep 2014 CytImmune Sciences enters into a manufacturing agreement with Coldstream Laboratories
  • 02 Jul 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events and (Service) therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top